Fähigkeit von Kondensationskeimzählern, Nanopartikel mit hydrophober und hydrophiler Oberfläche zu messen

Heute werden Nanopartikel zwar noch in relativ wenigen Produkten eingesetzt und meist kommen die Partikel im Produkt selbst als gebundene Partikel vor. Eine Exposition Endverbrauchers kann nicht ausgeschlossen werden, sie wird aber heute angesichts der geringen Verbreitung als eher unwahrscheinlich betrachtet. Was hingegen heute schon vermehrt vorkommen kann ist eine Exposition eines Arbeiters während des Herstellungs- oder Verarbeitungsprozesses eines Produkts. Auf diesen Bereich muss man daher ein grösseres Augenmerk legen. Um zu bestimmen, ob ein Arbeiter einer Nanopartikel-Exposition ausgesetzt ist, stehen heute verschiedene Messmethoden zur Verfügung. Die meisten Methoden fokussieren sich auf die Messung von Nanopartikel in der Luft, da die Aufnahme von Nanopartikel vor allem über die Atemwege stattfindet. Die heutige Technik erlaubt eine quantitative Ermittlung dieser Konzentration. Da die Technik mit dem Fokus auf Diesel- und Umweltpartikel entwickelt wurde, muss die Vertrauenswürdigkeit dieser Messgeräte für neue Industrie-Partikel mit spezifischen Eigenschaften erneut überprüft werden. Die Effizienz von drei CPC-Messgeräte (Condensation-Particle-Counters) Typen zum Nachweis der Luftkonzentration von Nanopartikel-Pulvern wurde miteinander verglichen. Als Resultat der Studie kann gefolgert werden, dass alle CPCs gleichermassen für die Abschätzung der Nanopartikel-Konzentration an Arbeitsplätzen in der Industrie verwendet werden können. Hierbei spielt es keine wesentliche Rolle, ob das Pulver eine hydrophile oder hydrophobe Oberfläche aufweist. Nur eines der drei hydrophilen Pulvern konnte mit dem Wasser CPC besser nachgewiesen werden als mit den anderen CPC desselben Herstellers.

Azathioprine and 6-Mercaptopurine use in the Swiss IBD cohort : adverse effects, causes of discontinuation and risk of "flares" according to 6-TG levels

Background: To characterize and analyze in the Swiss IBD Cohort: a) reported Azathioprine (AZA) and 6-Mercaptopurine (6-MP) adverse effects (AE), b) causes of discontinuation and c) response to therapy according to gastroenterologists' clinical judgment, d) whether level of 6-TGN < 235pmol/8 x108 red blood cells (RBC) is associated with a higher risk of "flare" occurrence. Methods: Retrospective statistical description, Cox model and Kaplan-Meier survival estimation. Results: 1499 patients with Crohn's Disease (CD) and 1066 with Ulcerative colitis (UC).

First Reported Successful Femoral Valve-in-Valve Transcatheter Aortic Valve Replacement Using the Edwards Sapien 3 Valve.

OBJECTIVES: Management of degenerated aortic valve bioprosthesis classically requires redo surgery, but transcatheter aortic valve-in-valve implantation is becoming a valid alternative in selected cases. In the case of a degenerated Mitroflow bioprosthesis, TAVR is associated with an additional challenge due to a specific risk of coronary occlusion. We aimed to assess the safety and feasibility of transfemoral valve-in-valve implantation of the new Edwards Sapien 3 (Edwards Lifesciences) in a degenerated Mitroflow bioprosthesis (Sorin Group, Inc). METHODS: We report here the safety and feasibility of transfemoral valve-in-valve implantation of a 23 mm Edwards Sapien 3 in a degenerated 25 mm Mitroflow valve and describe the specific assessment of the risk of coronary obstruction using a multi-imaging modality. RESULTS: The final result showed an absence of aortic regurgitation and a mean transvalvular gradient of 14 mm Hg. The patient had no major adverse cardiovascular events at 30-day follow-up. CONCLUSION: Transcatheter valve-in-valve implantation of an Edwards Sapien 3 in a degenerated Mitroflow is feasible and safe, considering a careful assessment of the risk of coronary obstruction with Mitroflow bioprosthesis due to leaflets mounted externally to the stent.

Significance of an isolated new right bundle branch block in a patient with chest pain.

Chest pain is a common presenting symptom in emergency departments, and a typical manifestation of acute myocardial infarction (AMI). Recognition of ECG changes in AMI is essential for timely diagnosis and treatment. Right bundle branch block (RBBB) may be an isolated sign of AMI, and was previously considered as a criterion for fibrinolytic therapy. Since the most recent European Society of Cardiology and American Heart Association guidelines in 2013, RBBB alone is no longer considered a diagnostic criterion of AMI, even if it occurs in the context of acute chest pain, as RBBB does not usually interfere with the interpretation of ST-segment alteration. Our case illustrates an acute septal myocardial infarction with an isolated RBBB, and thus the importance of recognising this pattern in order to permit timely diagnosis and treatment.

Low statin use in adults hospitalized with acute coronary syndrome.

OBJECTIVE: To assess recommended and actual use of statins in primary prevention of cardiovascular disease (CVD) based on clinical prediction scores in adults who develop their first acute coronary syndrome (ACS). METHOD: Cross-sectional study of 3172 adults without previous CVD hospitalized with ACS at 4 university centers in Switzerland. The number of participants eligible for statins before hospitalization was estimated based on the European Society of Cardiology (ESC) guidelines and compared to the observed number of participants on statins at hospital entry. RESULTS: Overall, 1171 (37%) participants were classified as high-risk (10-year risk of cardiovascular mortality ≥5% or diabetes); 1025 (32%) as intermediate risk (10-year risk <5% but ≥1%); and 976 (31%) as low risk (10-year risk <1%). Before hospitalization, 516 (16%) were on statins; among high-risk participants, only 236 of 1171 (20%) were on statins. If ESC primary prevention guidelines had been fully implemented, an additional 845 high-risk adults (27% of the whole sample) would have been eligible for statins before hospitalization. CONCLUSION: Although statins are recommended for primary prevention in high-risk adults, only one-fifth of them are on statins when hospitalized for a first ACS.